Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
出版年份 2021 全文链接
标题
Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis
作者
关键词
-
出版物
Cancers
Volume 13, Issue 2, Pages 213
出版商
MDPI AG
发表日期
2021-01-08
DOI
10.3390/cancers13020213
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- mRECIST for HCC: Performance and novel refinements
- (2020) Josep M. Llovet et al. JOURNAL OF HEPATOLOGY
- Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
- (2020) Sadal Refae et al. Scientific Reports
- The future of cancer immunotherapy: microenvironment-targeting combinations
- (2020) Yonina R. Murciano-Goroff et al. CELL RESEARCH
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
- (2020) Masatoshi Kudo Cancers
- Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab
- (2020) Daisuke Nishikawa et al. CANCER SCIENCE
- Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma
- (2020) Chang Gon Kim et al. JOURNAL OF HEPATOLOGY
- Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma
- (2020) Giulia Orsi et al. Targeted Oncology
- Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients
- (2020) Seung-Myoung Son et al. Scientific Reports
- Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib
- (2020) Thomas Yau et al. JAMA Oncology
- Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
- (2020) Petros Fessas et al. Journal for ImmunoTherapy of Cancer
- Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma
- (2020) Adi Kartolo et al. Immunotherapy
- Novel patterns of response under immunotherapy
- (2019) E Borcoman et al. ANNALS OF ONCOLOGY
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- Hepatocellular Carcinoma
- (2019) Augusto Villanueva NEW ENGLAND JOURNAL OF MEDICINE
- Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
- (2019) Li-Chun Lu et al. Liver Cancer
- Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response
- (2019) Bridget P. Keenan et al. Journal for ImmunoTherapy of Cancer
- Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients With Melanoma Treated With Pembrolizumab
- (2018) Richard W. Joseph et al. CLINICAL CANCER RESEARCH
- Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria
- (2018) M. Tazdait et al. EUROPEAN JOURNAL OF CANCER
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- (2018) Masatoshi Kudo et al. LANCET
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
- (2018) Ghassan K. Abou-Alfa et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach
- (2018) Daniëlle Krijgsman et al. Frontiers in Immunology
- Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment
- (2018) Li-Chun Lu et al. Liver Cancer
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Opposing roles of eosinophils in cancer
- (2018) Sonja C. S. Simon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab
- (2017) Tomoko Funazo et al. Journal of Thoracic Oncology
- Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Jordi Bruix et al. LANCET
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics
- (2017) Lesley Seymour et al. LANCET ONCOLOGY
- Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
- (2017) Paul C. Tumeh et al. Cancer Immunology Research
- Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients
- (2016) Leila Khoja et al. BRITISH JOURNAL OF CANCER
- Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib
- (2016) Shao-Lai Zhou et al. GASTROENTEROLOGY
- Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib
- (2016) Andrea Casadei Gardini et al. Oncotarget
- Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
- (2016) E. Liniker et al. OncoImmunology
- Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study
- (2016) Viktor H. Koelzer et al. Journal for ImmunoTherapy of Cancer
- Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells
- (2015) Philipp Müller et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
- (2015) Andrew X Zhu et al. LANCET ONCOLOGY
- Immunological landscape and immunotherapy of hepatocellular carcinoma
- (2015) Jesús Prieto et al. Nature Reviews Gastroenterology & Hepatology
- Patrolling monocytes control tumor metastasis to the lung
- (2015) R. N. Hanna et al. SCIENCE
- Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens
- (2015) Marina K Baine et al. Oncotarget
- Identification of a FOXP3+CD3+CD56+ population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma
- (2015) Xiaofeng Li et al. Scientific Reports
- Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous
- (2015) Ratnadeep Mukherjee et al. Scientific Reports
- Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF- 1
- (2014) H. Li et al. JOURNAL OF IMMUNOLOGY
- Cancer heterogeneity: implications for targeted therapeutics
- (2013) R Fisher et al. BRITISH JOURNAL OF CANCER
- Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis
- (2013) Fumitaka Arihara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunodominance and functional alterations of tumor-associated antigen-specific CD8+T-cell responses in hepatocellular carcinoma
- (2013) Tobias Flecken et al. HEPATOLOGY
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
- (2012) Hang Li et al. HEPATOLOGY
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Immune tolerance: What is unique about the liver
- (2009) Gisa Tiegs et al. JOURNAL OF AUTOIMMUNITY
- A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells
- (2008) Bastian Hoechst et al. GASTROENTEROLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started